Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Accumulated Expenses: 2018-2025

Historic Accumulated Expenses for Bicycle Therapeutics (BCYC) over the last 7 years, with Sep 2025 value amounting to $44.4 million.

  • Bicycle Therapeutics' Accumulated Expenses rose 12.86% to $44.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.4 million, marking a year-over-year increase of 12.86%. This contributed to the annual value of $41.2 million for FY2024, which is 30.90% up from last year.
  • Latest data reveals that Bicycle Therapeutics reported Accumulated Expenses of $44.4 million as of Q3 2025, which was down 0.38% from $44.5 million recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' Accumulated Expenses registered a high of $44.5 million during Q2 2025, and its lowest value of $9.7 million during Q1 2021.
  • Over the past 3 years, Bicycle Therapeutics' median Accumulated Expenses value was $34.1 million (recorded in 2023), while the average stood at $35.1 million.
  • In the last 5 years, Bicycle Therapeutics' Accumulated Expenses soared by 119.81% in 2023 and then declined by 24.49% in 2024.
  • Bicycle Therapeutics' Accumulated Expenses (Quarterly) stood at $14.2 million in 2021, then surged by 85.71% to $26.5 million in 2022, then climbed by 19.12% to $31.5 million in 2023, then soared by 30.90% to $41.2 million in 2024, then rose by 12.86% to $44.4 million in 2025.
  • Its last three reported values are $44.4 million in Q3 2025, $44.5 million for Q2 2025, and $34.0 million during Q1 2025.